Travis Murdoch

CIK: 0001845681

Transaction Breakdown

Open Market Buys (P)1 (50.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)1 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

BRVE

Braveheart Bio, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (2 total)

BRVE
Braveheart Bio, Inc.
Aug 7, 2026
Purchase(P)
Direct
83.3K shares at avg. $18.00$1.5M
BRVE
Braveheart Bio, Inc.
Aug 5, 2026
Award(A)
Stock Option (Right to Buy)
Direct
550K shares-

		Type	Shares	Price		Ownership
Aug 7, 2026	BRVE Braveheart Bio, Inc.	Purchase(P)	83,333	$18.00	$1,499,994	Direct
Aug 5, 2026	BRVE Braveheart Bio, Inc.	Award(A) Stock Option (Right to Buy)	550,000	-	-	Direct

1-2 of 2 transactions

About Murdoch Travis

Murdoch Travis (SEC CIK 0001845681) files insider reports with the SEC as CEO and President of Braveheart Bio, Inc. (BRVE).

Signal8 holds 2 ownership filings by Murdoch Travis (1 Form 3, 1 Form 4), filed between Aug 5, 2026 and Aug 7, 2026. Those filings report 2 transactions, from Aug 5, 2026 to Aug 7, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Murdoch Travis's filings is in SAN FRANCISCO, CA.

Recent filings by Murdoch Travis

Aug 7, 2026: Open-market purchase of BRVE shares (Form 4, code P).
Aug 5, 2026: Grant or award of BRVE derivative securities (Form 4, code A).

Other insiders filing for Braveheart Bio, Inc. (BRVE)

Agarwala Vineeta, Director
AH Bio Fund IV, L.P., 10% Owner
Chimovits Erez, Director
ORBIMED ADVISORS LLC, Director
Jiangsu Hengrui Pharmaceuticals Co., Ltd., 10% Owner
Forbion Growth Opportunities Fund III Cooperatief U.A., 10% Owner

How to read Form 4 transaction codes